Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Aug;40(8):1835–1842. doi: 10.1128/aac.40.8.1835

Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.

T Takenouchi 1, F Tabata 1, Y Iwata 1, H Hanzawa 1, M Sugawara 1, S Ohya 1
PMCID: PMC163426  PMID: 8843290

Abstract

The elevated expression of the norA gene is responsible for efflux-mediated resistance to quinolones in Staphylococcus aureus (E.Y.W. Ng, M. Trucksis, and D.C. Hooper, Antimicrob. Agents Chemother. 38:1345-1355, 1994). For S. aureus transformed with a plasmid containing the cloned norA gene, SA113(pTUS20) (H. Yoshida, M. Bogaki, S. Nakamura, K. Ubukata, and M. Konno, J. Bacteriol. 172:6942-6949, 1990), and an overexpressed mutant, SA-1199B (G.W. Kaatz, S.M. Seo, and C.A. Ruble, J. Infect. Dis. 163:1080-1086, 1991), the MICs of norfloxacin increased 16 and 64 times compared with its MICs for the recipient and wild-type strains, SA113 and SA-1199, respectively. MICs of CS-940, however, increased only two and eight times, even though these two fluoroquinolones are similarly hydrophilic (apparent logPs of approximately -1). No good correlation was found, among 15 developed and developing quinolones, between the increment ratio in MICs and hydrophobicity (r = 0.61). Analysis of the quantitative structure-activity relationship among 40 fluoroquinolones revealed that the MIC increment ratio was significantly correlated with the bulkiness of the C-7 substituent and bulkiness and hydrophobicity of the C-8 substituent of fluoroquinolones (r = 0.87) and not with its molecular hydrophobicity (r = 0.47). Cellular accumulation of norfloxacin in SA-1199B was significantly lower than that in SA-1199, and it was increased by addition of carbonyl cyanide m-chlorophenyl hydrazone. On the other hand, accumulations of CS-940 in these strains were nearly identical, and they were not affected by addition of the protonophore.

Full Text

The Full Text of this article is available as a PDF (248.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. E., Shekhtman E. M., Zechiedrich E. L., Schmid M. B., Cozzarelli N. R. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell. 1992 Oct 16;71(2):277–288. doi: 10.1016/0092-8674(92)90356-h. [DOI] [PubMed] [Google Scholar]
  2. Asuquo A. E., Piddock L. J. Accumulation and killing kinetics of fifteen quinolones for Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother. 1993 Jun;31(6):865–880. doi: 10.1093/jac/31.6.865. [DOI] [PubMed] [Google Scholar]
  3. Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother. 1990 Dec;26 (Suppl F):165–179. doi: 10.1093/jac/26.suppl_f.165. [DOI] [PubMed] [Google Scholar]
  4. Bazile S., Moreau N., Bouzard D., Essiz M. Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones. Antimicrob Agents Chemother. 1992 Dec;36(12):2622–2627. doi: 10.1128/aac.36.12.2622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brockbank S. M., Barth P. T. Cloning, sequencing, and expression of the DNA gyrase genes from Staphylococcus aureus. J Bacteriol. 1993 Jun;175(11):3269–3277. doi: 10.1128/jb.175.11.3269-3277.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bryan L. E., Bedard J. Impermeability to quinolones in gram-positive and gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):232–239. doi: 10.1007/BF01966995. [DOI] [PubMed] [Google Scholar]
  7. Chapman J. S., Georgopapadakou N. H. Routes of quinolone permeation in Escherichia coli. Antimicrob Agents Chemother. 1988 Apr;32(4):438–442. doi: 10.1128/aac.32.4.438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Denis A., Moreau N. J. Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition. J Antimicrob Chemother. 1993 Sep;32(3):379–392. doi: 10.1093/jac/32.3.379. [DOI] [PubMed] [Google Scholar]
  9. Fasching C. E., Tenover F. C., Slama T. G., Fisher L. M., Sreedharan S., Oram M., Willard K., Sinn L. M., Gerding D. N., Peterson L. R. gyrA mutations in ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus from Indiana, Minnesota, and Tennessee. J Infect Dis. 1991 Nov;164(5):976–979. doi: 10.1093/infdis/164.5.976. [DOI] [PubMed] [Google Scholar]
  10. Ferrero L., Cameron B., Manse B., Lagneaux D., Crouzet J., Famechon A., Blanche F. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol. 1994 Aug;13(4):641–653. doi: 10.1111/j.1365-2958.1994.tb00458.x. [DOI] [PubMed] [Google Scholar]
  11. Furet Y. X., Deshusses J., Pechère J. C. Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 1992 Nov;36(11):2506–2511. doi: 10.1128/aac.36.11.2506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Goswitz J. J., Willard K. E., Fasching C. E., Peterson L. R. Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob Agents Chemother. 1992 May;36(5):1166–1169. doi: 10.1128/aac.36.5.1166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hirai K., Aoyama H., Irikura T., Iyobe S., Mitsuhashi S. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother. 1986 Mar;29(3):535–538. doi: 10.1128/aac.29.3.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hooper D. C. Quinolone mode of action. Drugs. 1995;49 (Suppl 2):10–15. doi: 10.2165/00003495-199500492-00004. [DOI] [PubMed] [Google Scholar]
  15. Hooper D. C., Wolfson J. S. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991 Feb 7;324(6):384–394. doi: 10.1056/NEJM199102073240606. [DOI] [PubMed] [Google Scholar]
  16. Ito H., Yoshida H., Bogaki-Shonai M., Niga T., Hattori H., Nakamura S. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Sep;38(9):2014–2023. doi: 10.1128/aac.38.9.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kaatz G. W., Barriere S. L., Schaberg D. R., Fekety R. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J Antimicrob Chemother. 1987 Nov;20(5):753–758. doi: 10.1093/jac/20.5.753. [DOI] [PubMed] [Google Scholar]
  18. Kaatz G. W., Seo S. M., Ruble C. A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1993 May;37(5):1086–1094. doi: 10.1128/aac.37.5.1086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kaatz G. W., Seo S. M., Ruble C. A. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J Infect Dis. 1991 May;163(5):1080–1086. doi: 10.1093/infdis/163.5.1080. [DOI] [PubMed] [Google Scholar]
  20. Lewis K. Multidrug resistance pumps in bacteria: variations on a theme. Trends Biochem Sci. 1994 Mar;19(3):119–123. doi: 10.1016/0968-0004(94)90204-6. [DOI] [PubMed] [Google Scholar]
  21. Luttinger A. The twisted 'life' of DNA in the cell: bacterial topoisomerases. Mol Microbiol. 1995 Feb;15(4):601–606. doi: 10.1111/j.1365-2958.1995.tb02369.x. [DOI] [PubMed] [Google Scholar]
  22. McCaffrey C., Bertasso A., Pace J., Georgopapadakou N. H. Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Antimicrob Agents Chemother. 1992 Aug;36(8):1601–1605. doi: 10.1128/aac.36.8.1601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mortimer P. G., Piddock L. J. A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1991 Nov;28(5):639–653. doi: 10.1093/jac/28.5.639. [DOI] [PubMed] [Google Scholar]
  24. Ng E. Y., Trucksis M., Hooper D. C. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother. 1994 Jun;38(6):1345–1355. doi: 10.1128/aac.38.6.1345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nikaido H., Thanassi D. G. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother. 1993 Jul;37(7):1393–1399. doi: 10.1128/aac.37.7.1393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ohshita Y., Hiramatsu K., Yokota T. A point mutation in norA gene is responsible for quinolone resistance in Staphylococcus aureus. Biochem Biophys Res Commun. 1990 Nov 15;172(3):1028–1034. doi: 10.1016/0006-291x(90)91549-8. [DOI] [PubMed] [Google Scholar]
  27. Reece R. J., Maxwell A. DNA gyrase: structure and function. Crit Rev Biochem Mol Biol. 1991;26(3-4):335–375. doi: 10.3109/10409239109114072. [DOI] [PubMed] [Google Scholar]
  28. Saier M. H., Jr Computer-aided analyses of transport protein sequences: gleaning evidence concerning function, structure, biogenesis, and evolution. Microbiol Rev. 1994 Mar;58(1):71–93. doi: 10.1128/mr.58.1.71-93.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Schaefler S. Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. J Clin Microbiol. 1989 Feb;27(2):335–336. doi: 10.1128/jcm.27.2.335-336.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Shalit I., Berger S. A., Gorea A., Frimerman H. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother. 1989 Apr;33(4):593–594. doi: 10.1128/aac.33.4.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Takenouchi T., Ishii C., Sugawara M., Tokue Y., Ohya S. Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob Agents Chemother. 1995 Jul;39(7):1414–1418. doi: 10.1128/aac.39.7.1414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Takács-Novák K., Noszál B., Hermecz I., Keresztúri G., Podányi B., Szász G. Protonation equilibria of quinolone antibacterials. J Pharm Sci. 1990 Nov;79(11):1023–1028. doi: 10.1002/jps.2600791116. [DOI] [PubMed] [Google Scholar]
  33. Trucksis M., Wolfson J. S., Hooper D. C. A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J Bacteriol. 1991 Sep;173(18):5854–5860. doi: 10.1128/jb.173.18.5854-5860.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ubukata K., Itoh-Yamashita N., Konno M. Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1989 Sep;33(9):1535–1539. doi: 10.1128/aac.33.9.1535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wang J. C. DNA topoisomerases. Annu Rev Biochem. 1985;54:665–697. doi: 10.1146/annurev.bi.54.070185.003313. [DOI] [PubMed] [Google Scholar]
  36. Yoshida H., Bogaki M., Nakamura S., Ubukata K., Konno M. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol. 1990 Dec;172(12):6942–6949. doi: 10.1128/jb.172.12.6942-6949.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES